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Secretory diarrhea is the leading cause of infectious
diarrhea in humans. Secretory diarrhea may be caused
by binding of heat-stable enterotoxins to the intestinal
receptor guanylyl cyclase C (GCC). Activation of GCC
catalyzes the formation of cGMP, initiating a signaling
cascade that opens the cystic fibrosis transmembrane
conductance regulator chloride channel at the apical
cell surface. To identify proteins that regulate the traf-
ficking or function of GCC, we used the unique COOH
terminus of GCC as the “bait” to screen a human intes-
tinal yeast two-hybrid library. We identified a novel pro-
tein, IKEPP (intestinal and kidney-enriched PDZ pro-
tein) that associates with the COOH terminus of GCC in
biochemical assays and by co-immunoprecipitation.
IKEPP is expressed in the intestinal epithelium, where
it is preferentially accumulated at the apical surface.
The GCC-IKEPP interaction is not required for the effi-
cient targeting of GCC to the apical cell surface. Rather,
the association with IKEPP significantly inhibits heat-
stable enterotoxin-mediated activation of GCC. Our
findings are the first to identify a regulatory protein
that associates with GCC to modulate the catalytic ac-
tivity of the enzyme and provides new insights in mech-
anisms that regulate GCC activity in response to bacte-
rial toxin.
Guanylyl cyclase C (GCC) is the receptor for heat-stable
enterotoxins (STa)1 secreted by Escherichia coli and other en-
teric bacteria. STa binding to GCC increases intracellular
cGMP and initiates a signaling cascade, leading to the phos-
phorylation of the cystic fibrosis transmembrane conductance
regulator (CFTR) at the apical surface of gastrointestinal epi-
thelial cells. Phosphorylation of CFTR opens the channel, re-
sulting in the net efflux of ions and water into the intestinal
lumen. The endogenous ligands for GCC include guanylin,
uroguanylin, and lymphoguanylin, which are thought to regu-
late ion transport in epithelial tissues (1–3).
GCC is a member of a family of transmembrane proteins that
includes receptors for natriuretic peptides and egg-activating
peptides as well as several orphan receptors (4). All receptor
GCs with a single transmembrane domain share a common
topology. There is an NH2-terminal extracellular ligand-bind-
ing domain and a large cytosolic domain composed of a kinase
homology domain and a catalytic domain. Following the cata-
lytic domain, GCC contains an extended COOH terminus of 63
amino acids (COOH-terminal extension peptide (CTEP)) that is
not found in the natriuretic peptide receptors (5). The CTEP is
well conserved and contains a consensus protein kinase C
phosphorylation site that potentiates cGMP-mediated signal-
ing by phorbol esters (6). GCC proteins lacking the 63-amino
acid CTEP lose the ability to respond to STa (6, 7), suggesting
that this unique sequence plays a role in GCC activation. Since
GCC is the only receptor guanylyl cyclase localized predomi-
nately at the apical membrane of epithelial cells, CTEP may
also play a role targeting the receptor to the apical cell surface.
To determine whether the COOH terminus of GCC partici-
pates in protein-protein interactions that may regulate its tar-
geting or function, we screened a human intestinal epithelial
enriched yeast two-hybrid library using CTEP as “bait.” We
found that GCC associates via its COOH terminus with a novel
protein containing four PDZ domains. Based on its domain
organization and restricted mRNA distribution, we named this
protein IKEPP (intestinal and kidney enriched PDZ Protein).
IKEPP is accumulated at the apical membrane of human in-
testinal epithelial cells and associates with GCC in a cellular
context. Mutagenesis studies indicate that association with
PDZ proteins is not required for efficient targeting of GCC to
the apical surface. Rather, the interaction of IKEPP and GCC
inhibits receptor activation by STa. Thus, GCC activity may be
modulated by interaction with accessory proteins, thereby pro-
viding additional means to regulate signaling via guanylyl
cyclase receptors.
EXPERIMENTAL PROCEDURES
cDNA Library Generation, Plasmid Construction, Two-hybrid
Screens—All cDNA inserts were generated by PCR, cloned into comple-
mentary restriction endonuclease sites of the appropriate plasmids, and
verified by sequencing; specific details are available upon request. A
human intestinal epithelial enriched cDNA library was generated by
cloning poly(dT)-primed cDNA into the HybriZAP bacteriophage  vec-
tor followed by amplification and in vivo mass excision to generate a
two-hybrid library in pAD-GAL4 (Stratagene). The yeast binding do-
main (BD) plasmid pPC86BD was generated by digesting the parental
vectors, pPC97 (GAL4BD and LEU2) and pPC86 (GAL4AD and TRP1)
(8), with ApaI and BamHI. These fragments were then ligated into the
opposite backbone vector to give pPC86BD and pPC97AD.
cDNA encoding full-length CTEP was amplified by PCR using
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pBS.GCC as template; the PCR products were inserted in frame to the
corresponding sites in pPC86BD. The yeast strain AH109 was sequen-
tially transformed with pPC86BD.CTEP and 20 g of a human intes-
tinal cDNA library as described (9). A 2.2-kb cDNA clone encoding a
novel protein was isolated twice in the screen. After sequencing and
Northern blot analysis, this clone was named IKEPP (intestinal and
kidney enriched PDZ protein). To obtain upstream coding sequences we
performed 5 rapid amplification of cDNA ends using Marathon-Ready
Human Kidney cDNA (CLONTECH); products were cloned into pTAdv
(CLONTECH) and sequenced. Human multiple tissue northern blots
and a multiple expression array blot (CLONTECH) were probed with
32P-labeled random-primed cDNA probe corresponding to the IKEPP
3-untranslated region (nucleotides 1565–2120) as described (10).
Antisera Generation and Immunoblot Analysis—Rabbit antisera di-
rected against the COOH terminus of human IKEPP were generated in
rabbits using residues 484–505 of IKEPP coupled with keyhole limpet
cyanin as immunogen. Rabbit polyclonal antisera were also generated
using His-IKEPP fusion protein as immunogen. The pET.IKEPP plas-
mid was transformed into BL21(DE3, pLysS) Escherichia coli and
grown to the appropriate cell density at 37 °C. IKEPP expression was
induced by the addition of 1 mM isopropyl-1-thio--D-galactopyranoside
for 3 h at 37 °C and purified from the insoluble fraction.
To prepare cell lysates, cultured cells were washed with ice-cold
phosphate-buffered saline (50 mM NaPO4, 150 mM NaCl, pH 7.4) and
isolated by scraping in ice-cold homogenization buffer containing 20 mM
Hepes, pH 7.4, 150 mM NaCl, 2 mM phenylmethylsulfonyl fluoride, 1
g/ml leupeptin. The homogenates were centrifuged at 100,000  g for
1 h to generate soluble and particulate fractions. Protein concentrations
were determined using the BCA protein assay kit (Pierce); samples
were fractionated by SDS-PAGE and transferred to Immobilon-P (Mil-
lipore Corp.). Western blots were performed using rabbit anti-IKEPP
IgG (NC368 or NC369; 1:2000) and visualized using ECL.
Protein Interaction Assays—In vitro binding assays and co-immuno-
precipitations were performed as described (11). For immunoprecipita-
tion of overexpressed HA-GCC and IKEPP, COS7 cells were transfected
with cDNAs encoding IKEPP and HA-GCC or HA-GCC4 with Fu-
GENE6 (Roche Molecular Biochemicals). After 48 h, the cells were lysed
in TBS (100 mM Tris-HCl, 150 mM NaCl, pH 7.5), 1% Triton X-100, and
protease inhibitors. Mouse anti-HA or purified normal mouse IgG (2 g)
was added to the cell lysate and incubated overnight at 4 °C. Immune
complexes were collected on protein G-agarose and washed extensively
in TBS buffer plus 0.1% Triton X-100. Bound proteins were resolved by
SDS-PAGE and analyzed by Western blotting with HA or IKEPP
antisera.
Confocal Microscopy—Stable MCDK type II cell lines expressing
HA-GCC or HA-GCC4 were generated as described (10). MDCK or
Caco2 cells were grown on Transwell filters (Costar) until confluent
monolayers were observed, and transepithelial resistances, with filter
subtraction, were greater than 1000 ohmscm2 or 400 ohmscm2, respec-
tively. Immunofluorescent staining was performed as described (10,
11). The localization of IKEPP was also studied in sections of formalin-
fixed human colon and small intestine. Sections were prepared as
described previously (12), stained with rabbit anti-IKEPP IgG (NC369;
diluted 1:1500), and processed using the Vectastain Elite ABC kit
(Vector Laboratories, Inc.); sections were counterstained with methyl
green to label nuclei.
GCC Activity Assays—COS7 cells, plated on six-well culture dishes at
a density of 4  105 24 h prior to transfection, were incubated in
FuGENE 6 as described in the instruction manual. After 48 h, the
culture medium was removed, the cells were incubated in serum-free
Dulbecco’s modified Eagle’s medium/F-12 containing 100 M isobutyl-
methylxanthine for 15 min, and 25 units/ml STa (Sigma) was added to
each well for 20 min. The cells were washed twice in ice-cold phosphate-
buffered saline, lysed in 0.1 M HCl for 20 min, and collected by centrif-
ugation at 4 °C. For dose-response curves, cells were handled as de-
scribed except that 2  105 cells were seeded in 12-well culture dishes
24 h prior to transfection. Following transfection, STa was added to the
cells at various concentrations for 30 min in the presence of 100 M
isobutylmethylxanthine. Cells were harvested, and cGMP production
was measured in both the cell lysate and culture medium using a
Correlate-EIA Direct Cyclic GMP Enzyme Immunoassay Kit (Assay
Designs, Inc.).
RESULTS
Cloning and Characterization of a Novel GCC-interacting
Protein—In an attempt to isolate GCC-interacting proteins, we
used the yeast two-hybrid system to identify proteins that
interact with the CTEP of GCC. Screening of a human epithe-
lial enriched intestinal cDNA library yielded several potential
interactors that were His, and we further analyzed two clones
that exhibited robust -galactosidase activity. The specificity of
the interaction in yeast was verified by transforming the acti-
vation domain plasmid along with the original bait, an empty
bait vector, or a plasmid encoding an unrelated bait (data not
shown).
Sequence analysis revealed that the cDNA inserts were 2.4
kb and contained identical cDNA sequence with an open read-
ing frame of 1503 nucleotides. A protein pattern search using
Pfam indicated that the open reading frame encoded a protein
containing four PDZ domains. The gene was mapped to a
region of chromosome 11q23 when searched against the human
genome draft data base. The full-length cDNA with an open
reading frame of 1518 nucleotides was predicted from genomic
DNA and confirmed by 5 rapid amplification of cDNA ends
using human kidney cDNA as template. The open reading
frame predicts a protein of 505 amino acids with a theoretical
molecular mass of 54.2 kilodaltons and a pI of 5.46.
On Northern blots, we detected 2.3- and 2.5-kb messages in
human kidney (Fig. 1A), although prolonged exposures of the
blots revealed that the mRNAs were also expressed in the
small intestine and colon. Since GCC mRNA is abundantly
expressed in the intestine (5), we also probed a human expres-
sion array containing poly(A) RNA prepared from multiple
gastrointestinal tissues. We found that mRNA was easily de-
tected in the kidney and along the entire gastrointestinal tract,
from the duodenum to the colon (Fig. 1B). The mRNA was not
detected in any other human tissue including brain, heart,
skeletal muscle, or cells of hematopoietic origin (data not
shown). Based on the relatively restricted distribution of the
mRNA and the domain structure of the predicted protein, we
named this novel protein IKEPP.
IKEPP Is Related to Other Epithelial Enriched PDZ Pro-
teins—A BLAST search of the nonredundant GenBankTM data
base with the IKEPP protein sequence revealed that IKEPP is
most closely related to PDZK1 (PDZ domain containing pro-
tein-1; also called CAP70), a protein with four PDZ domains
(13, 14). IKEPP and PDZK1 are closely related to two other
human epithelial PDZ proteins, EBP50 (ezrin-radixin-moesin-
binding phosphoprotein-50; also called NHERF1) and E3KARP
(NHE3 kinase A regulatory protein; also called NHERF2),
which each contain two PDZ domains (Fig. 1C) followed by a
COOH-terminal domain that associates with the NH2 terminus
of ezrin, radixin, and moesin to link these proteins to the actin
cytoskeleton (15). An analysis of the sequence identity between
the individual IKEPP PDZ domains and the PDZ domains of
EBP50, E3KARP, and PDZK1 indicates that PDZ1 and PDZ4
of IKEPP are most unique, whereas PDZ2 and PDZ3 of IKEPP
share between 30 and 50% identity with the PDZ domains of
these related proteins (Fig. 1D). Furthermore, IKEPP is prob-
ably the human orthologue of the mouse type IIa sodium/
inorganic phosphate cotransporter-associated protein (Na/Pi-
Cap2), since both proteins contain four tandem PDZ domains,
share 77% sequence identity, and are expressed in the kidney
and intestine (16).
PDZ domains are composed of six  sheets (A–F), capped
by two  helices (A and B), which form a peptide-binding
groove that interacts with, at least, the last four C-terminal
amino acids of interacting proteins (17). In general, PDZ do-
mains recognize peptide sequences that contain a hydrophobic
residue at the extreme COOH terminus through a conserved
carboxylate-binding pocket most often formed by the sequence
Arg/Lys-X-X-X--Gly-Phe (where  represents a hydrophobic
amino acid) (18). The carboxylate loop of PDZ domains in
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IKEPP, PDZK1, EBP50, and E3KARP contain the general con-
sensus, Arg/Lys-X-X-Tyr/Phe-Gly-Phe, with the exception of
IKEPP PDZ4, which possesses a Pro residue rather than the
Arg/Lys (Fig. 1D). In the carboxylate-binding pocket, the Arg/
Lys residue is responsible for ordering a water molecule that
interacts with the terminal carboxylate of the ligand (17).
Therefore, the C-terminal residue(s) of proteins that associate
with IKEPP PDZ4 will probably differ from the ligands recog-
nized by PDZK1, EBP50, E3KARP, and IKEPP PDZ domains
1–3.
The 2-position of the preferred peptide ligand is used to
categorize the PDZ domains as class I (2 Ser/Thr), class II (2
hydrophobic), and a lesser defined class III, which deviate from
class I and II (18–20). The specificity of the 2 interaction is
coordinated by the first residue of the second  helix of the PDZ
domain (B1) (18). At the B1 position, class I PDZ domains
contain a conserved His residue (17, 21), whereas class II
domains possess a hydrophobic residue (22). To the best of our
knowledge, all of the published binding partners of PDZK1,
EBP50, and E3KARP, as well as the binding partners our
laboratory has identified for IKEPP, contain a Ser/Thr at the
2-position of the PDZ binding motif. Based on this structural
similarity, we predict that IKEPP is a member of the super-
family of class I PDZ proteins. Sequence analysis of the indi-
vidual PDZ domains of IKEPP, however, reveals that IKEPP
PDZ1 and PDZ4 lack the conserved His residue characteristic
of class I PDZ domains. In the B1 position, a Tyr residue
(IKEPP PDZ1) has been shown to prefer ligands containing a
2 Asp residue, whereas an Asp residue (IKEPP PDZ4) inter-
acts with peptides with a 2 Tyr (20, 23).
Localization and Distribution of IKEPP in Human Cells and
Tissues—To evaluate the subcellular distribution of IKEPP, we
generated rabbit polyclonal antisera directed against the
COOH-terminal 15 amino acids of human IKEPP or the recom-
binant full-length protein. These antisera were first tested by
Western blot analysis using full-length human IKEPP gener-
ated by coupled in vitro transcription/translation. Whereas pre-
immune sera did not detect proteins in the reticulocyte lysates,
both antibodies reliably detected full-length IKEPP (Fig. 2A).
We further tested the specificity of our IKEPP antisera by
Western blot analysis of EBP50, E3KARP, and PDZK1 and
found that both IKEPP antisera specifically recognize recom-
binant IKEPP and do not cross-react with these related pro-
teins (Fig. 2A). Recombinant E3KARP contains fewer methio-
nine residues than IKEPP, PDZK1, and EBP50 and was
visualized with prolonged exposure to the PhosphorImager
screen.
We first examined the expression of IKEPP in cultured hu-
man cell lines and found that the protein was expressed in
whole cell lysates of two intestinal epithelial cell lines, T84 and
Caco2 (Fig. 2B); much less protein was detected in an airway
epithelial cell line (16HBE14o) or in hEK293 cells. A significant
FIG. 1. Identification of a novel PDZ protein preferentially expressed in the intestine and kidney. A, a multiple tissue Northern blot
(CLONTECH) was probed with a random primed 32P-labeled probe generated against the IKEPP 3-untranslated region. The blot was stripped and
incubated with a -actin probe. Similar results were obtained in two separate blots. B, a multiple tissue array was probed with the same IKEPP
probed used in A; all other tissues showed no signal and were deleted from the figure. C, schematic representation of IKEPP and related PDZ
proteins. PDZ domains are numbered, and ezrin-radixin-moesin binding motifs are indicated by the letter E. The proteins are drawn to scale, and
the amino acid numbers are as shown. D, the amino acid sequences of the individual PDZ domains of IKEPP, PDZK1, EBP50, and E3KARP were
aligned using DNASTAR software. At each position, the most commonly conserved residues between sequences are shown in black boxes, whereas
similarly charged residues are shaded in gray. The predicted secondary structures of the PDZ domains, based on the crystal structure of EBP50
PDZ1 are also shown.
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fraction of the IKEPP protein was found in the particulate frac-
tion of Caco2 and T84 cells (Fig. 2C). We next examined the
localization of IKEPP in Caco2 cells grown to confluence on
Transwell filters and found IKEPP preferentially accumulated in
the subapical compartment and at the apical membrane
(Fig. 3A); similar results were obtained with colonic T84 cells
(data not shown). In normal human ileum and colon, IKEPP was
preferentially accumulated at the apical surface and was visual-
ized in cells of the crypt and villus (Fig. 3B). GCC is also ex-
pressed at the apical surface of intestinal epithelial cells (24).
Thus, the distribution of IKEPP in human intestine is consistent
with the possibility that the GCC and IKEPP associate in vivo.
Characterization of the IKEPP-GCC Interaction—We further
characterized the interaction between GCC and IKEPP. Since
GCC terminates with the amino acid sequence STYF, a type I
PDZ binding motif, we tested whether the COOH-terminal four
amino acids of CTEP mediated the interaction with IKEPP. We
immobilized GST, GST-CTEP full-length, or GST-CTEP4 fu-
sion proteins on glutathione-agarose beads and incubated the
affinity resins with radiolabeled IKEPP. We found that IKEPP
bound GST-CTEP but not GST or GST-CTEP4 (Fig. 4A). We
obtained similar results in overlay assays (data not shown),
indicating that the last four amino acid residues (SYTF) of GCC
are required for the direct association with IKEPP.
IKEPP has four PDZ domains that probably bind different
ligands. Therefore, we determined which IKEPP PDZ domains
are capable of associating with CTEP. To do this, we generated
histidine-tagged fusion proteins consisting of PDZ1, PDZ2,
PDZ3, or PDZ4 of IKEPP and tested which of the radiolabeled
fusion proteins associated with full-length GST-CTEP immobi-
lized on glutathione-agarose beads. We found that radiolabeled
PDZ3 bound specifically to full-length GST-CTEP, but not GST
or GST-CTEP4. This interaction was not detected for PDZ1,
PDZ2, and PDZ4 (Fig. 4B). Since IKEPP shares homology with
EBP50, E3KARP, and PDZK1, we immobilized GST-CTEP and
GST-CTEP4 on glutathione-agarose beads and tested
whether radiolabeled PDZK1, EBP50, or E3KARP could asso-
ciate with CTEP. We found that PDZK1, but not EBP50 or
E3KARP, associates with GST-CTEP in pull-down assays
(Fig. 4C).
To determine whether full-length IKEPP could associate
with full-length GCC, we incubated GST or GST-IKEPP with
whole cell lysates prepared from cells overexpressing HA-
tagged GCC (HA-GCC). HA-GCC associated with GST-IKEPP
but not with GST (Fig. 4D). GCC may be tightly associated with
the subapical cytoskeleton in the intestinal epithelium (25) and
is not easily solubilized from cell membranes in buffers com-
patible with maintaining protein-protein interactions. There-
fore we used an overexpression strategy to study the associa-
tion of GCC and IKEPP in nonepithelial cells. COS7 cells were
transiently transfected with cDNAs encoding IKEPP plus HA-
GCC or IKEPP plus HA-GCC4. Cell lysates were prepared in
buffers containing 1% Triton X-100, which is known to remove
GCC from cell membranes in COS7 cells (5), and the cell
lysates were incubated with control IgG or HA antibody. We
found that IKEPP was not associated with control IgG but was
easily detected in HA-GCC immunoprecipitates (Fig. 4E).
Moreover, IKEPP was not found in HA immunoprecipitates
FIG. 2. Characterization of IKEPP antisera and analysis of
IKEPP protein expression. A, radiolabeled IKEPP, PDZK1, EBP50,
and E3KARP were generated by in vitro transcription/translation in
the presence of [35S]methionine. Five l of each reaction was analyzed
by Western blot with antisera generated using full-length recombinant
IKEPP (NC368) or IKEPP residues 484–505 (NC369); the same mem-
brane was analyzed by PhosphorImager analysis (35S Met). Recombi-
nant E3KARP contains fewer methionine residues but is visualized
with prolonged exposure to the screen. B, whole cell lysates (50 g) were
analyzed by Western blot with rabbit anti-IKEPP (NC 368; 1:1000) or
mouse anti-actin. C, cultured T84 and Caco-2 cells were lysed in ho-
mogenization buffer plus protease inhibitors, and soluble and particu-
late fractions were prepared by differential centrifugation. Equal ratios
of each fraction were analyzed by Western blot using NC368 (1:1000).
Each blot is representative of three or four experiments.
FIG. 3. Localization of IKEPP. A, Caco-2 cells grown on Transwell
filters were fixed, permeabilized, blocked, and stained with preimmune
antisera or rabbit anti-IKEPP (NC369; 1:1500) followed by goat anti-
rabbit IgG coupled with Oregon Green (1:500). Texas Red-conjugated
phalloidin (1:500) was added to stain filamentous actin, and xz sections
were analyzed by confocal microscopy (scale bar, 10 m). B, represent-
ative paraffin-embedded 6-m sections of human colon (upper panels)
or small intestine (lower panels) were stained with preimmune antisera
or NC369 (1:1500). The arrows indicate regions of specific staining.
Sections were processed using Vectastain Elite ABC kit (scale bar, 50
m).
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from cells co-expressing HA-GCC4 plus IKEPP (Fig. 4E).
Thus, we conclude that GCC and IKEPP associate in cells and
that the association requires an intact GCC COOH terminus.
Function of the GCC-IKEPP Interaction—Interaction with
PDZ proteins may be involved in selectively targeting proteins
to apical or basolateral cell surfaces in epithelial cells (26–28).
Therefore, we tested whether the COOH-terminal STYF se-
quence in GCC was involved in targeting the receptor to the
apical cell surface. We generated stable MDCK cell lines ex-
pressing HA-GCC or HA-GCC4, lacking the STYF residues
that mediate interaction with PDZ proteins. Full-length HA-
GCC was targeted to the apical cell surface and was not de-
tected at the basolateral membrane (Fig. 5A). Likewise, HA-
GCC4 was preferentially accumulated at the apical cell
surface of polarized MDCK cells (Fig. 5A). HA-GCC and HA-
GCC4 were visualized at the apical membrane in nonperme-
abilized cells, further suggesting that the HA-GCC and HA-
GCC4 proteins were on the cell surface (data not shown).
Thus, we conclude that interaction with apical membrane PDZ
proteins does not play a significant role in the targeting of GCC
to the apical cell surface in MDCK cells.
Bakre et al. recently compared the STa-induced desenstiti-
zation of GCC in intestinal epithelial cells and in transfected
fibroblasts and suggested that GCC catalytic activity might be
regulated by interaction with proteins selectively expressed in
epithelial cells (29). Therefore, we tested whether IKEPP mod-
ulated STa-mediated activation of GCC in transfected COS7
cells that do not express significant amounts of endogenous
IKEPP. Treatment of COS7 cells expressing HA-GCC with 25
units/ml STa for 20 min significantly increased intracellular
cGMP, whereas cGMP was undetected in mock-transfected
cells (data not shown). In cells co-expressing GCC and IKEPP,
25 units/ml STa also increased intracellular cGMP above back-
ground. cGMP levels, however, were reduced by 1.7-fold in
cells co-expressing HA-GCC and IKEPP compared with cells
transfected with HA-GCC and empty vector (Fig. 5B). In sim-
ilar experiments, intracellular cGMP levels were decreased in
COS7 cells expressing GCC and IKEPP by 1.5–2.5-fold com-
pared with cells expressing HA-GCC and empty vector follow-
ing incubation with 25 units/ml STa for 10–30 min (data not
shown). This cannot be explained by changes in the expression
of HA-GCC in the co-transfected cells, since the receptor was
easily detected in membrane fractions prepared from these
cells (Fig. 5B). Since the COOH terminus of GCC mediates the
interaction with IKEPP, we tested whether IKEPP expression
also inhibited STa-mediated activation of HA-GCC4. We ob-
served similar levels of STa-mediated cGMP in HA-GCC4
cells in the absence or presence of co-expressed IKEPP (Fig.
5B). Therefore, we conclude that IKEPP binding may inhibit
the catalytic activity of GCC and that the inhibition requires a
physical interaction between the receptor and IKEPP. To begin
to understand the mechanism of this inhibition, we transfected
COS7 cells with HA-GCC with or without IKEPP and assayed
cGMP accumulation over a range of STa concentrations. Appli-
FIG. 4. Analysis of the GCC-IKEPP interaction. A, GST, GST-CTEP full-length (FL), or GST-CTEP4 (4) were immobilized on glutathione-
agarose beads and incubated with 5 l of radiolabeled IKEPP. The bound fractions were resolved by SDS-PAGE and applied to PhosphorImager
screen; the arrow indicates radiolabeled IKEPP. B, radiolabeled IKEPP PDZ domains were incubated with GST-CTEP full-length or GST-CTEP4.
The bound fraction was separated by SDS-PAGE and visualized by PhosphorImager analysis. C, GST-CTEP full-length and GST-CTEP4 were
immobilized on glutathione-agarose beads and incubated with radiolabeled IKEPP, PDZK1, EBP50, or E3KARP. Bound proteins were visualized
by PhosphorImager analysis. The bottom panels show 20% of the input used in each reaction. E3KARP can be visualized with prolonged exposure
only in the input lane. D, 200 g of total cell lysate prepared from cells expressing HA-GCC was incubated at 4 °C overnight with GST or
GST-IKEPP. The bound fraction was analyzed by Western blot using HA antibody. I, input, representing 10% of the total cell lysate in each
reaction. E, COS7 cells were transfected with FUGENE6 plus 9 g of pCDNA.HA-GCC full-length or HA-GCC4 and 13.5 g of pCDNA.IKEPP.
Cell lysates were incubated with anti-mouse IgG or monoclonal HA.11. Immunoprecipitates were analyzed by Western blot with HA or IKEPP
antisera. The IgG band is indicated by the arrow, and molecular weight markers are as shown. IP, the antibody used for immunoprecipitation. All
panels are representative of 3–6 similar experiments.
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cation of STa resulted in a concentration-dependent accumula-
tion of cGMP in cells expressing HA-GCC plus vector or HA-
GCC plus IKEPP (Fig. 5C). Although we found no change in the
Vmax of the enzyme in the presence or absence of co-expressed
IKEPP, we found that IKEPP significantly increased the
amount of STa required for half-maximal activation of the
enzyme (Fig. 5C). The half-maximal effect of STa on cGMP
accumulation was 30 nM in the absence of IKEPP and in-
creased 10-fold with co-expressed IKEPP, indicating that as-
sociation with IKEPP alters the function of the receptor.
DISCUSSION
We report the cloning and initial characterization of IKEPP,
a novel PDZ protein expressed at the apical membrane of
human intestinal epithelial cells. IKEPP directly associates
with the COOH terminus of GCC, the heat-stable enterotoxin
receptor found at the apical surface of intestinal epithelial
cells. Our localization studies (Fig. 3) and co-immunoprecipita-
tion assays (Fig. 4E) support the hypothesis that IKEPP and
GCC may associate in cells. Furthermore, the association with
IKEPP inhibits the catalytic function of GCC, resulting in a
decreased responsiveness to STa (Fig. 5, B and C).
Sequence and structural analysis indicates that IKEPP is
most closely related to human PDZK1 (Fig. 1, C and D), a
protein identified in a yeast two-hybrid screen as a MAP17-
associated protein. PDZK1 also associates with cMOAT, a mul-
tidrug resistance transporter (13). The mouse orthologue of
PDZK1, named CAP70, was purified from kidney based on its
ability to associate with CFTR and was shown to potentiate
CFTR Cl channel activity (14). IKEPP and PDZK1 share
significant identity with EBP50 and E3KARP (Fig. 1D). These
proteins were first cloned as co-factors required for cAMP-
mediated inhibition of Na/H exchanger 3 (30, 31) and later
shown to associate with ezrin, radixin, and moesin (15). EBP50
and E3KARP can interact with receptors, ion channels, trans-
porters, signaling molecules, adaptor proteins, and proteins
that regulate membrane trafficking (32–37). Interestingly,
EBP50, E3KARP, and PDZK1 associate with CFTR (14, 32, 35),
a downstream effector of GCC (33). Therefore, it will be impor-
tant to test whether IKEPP compartmentalizes GCC and
CFTR together in a multiprotein complex at the apical cell
surface. It will also be important to compare the expression,
subcellular distribution, and binding partners of IKEPP and
PDZK1, since we find that CTEP can also bind PDZK1 in
biochemical assays (Fig. 4C).
Despite the overall sequence similarity between IKEPP,
PDZK1, EBP50, and E3KARP, PDZ1 and PDZ4 of IKEPP differ
at critical residues responsible for determining the specificity
of the interaction between the PDZ domain and COOH-termi-
nal ligand. Class I PDZ domains coordinate the interaction
with a Ser/Thr residue at the 2-position of their peptide
ligands through an B1 His residue. IKEPP PDZ4, however,
contains an B1 Asp residue, which has been shown to prefer-
entially interact with a 2 Tyr, rather than a Ser/Thr (20). In
IKEPP PDZ1, the conserved His is replaced by a Tyr residue,
which is predicted to result in the preferential binding of Asp at
the 2-position (23). Interestingly, the COOH terminus of
IKEPP ends in Ser-Asp-Leu-Leu, which we predict based on
sequence analysis, to be a ligand for IKEPP PDZ1. Conse-
quently, this interaction might regulate IKEPP PDZ1 interac-
tion with other proteins via competitive inhibition or serve as
the basis for potential IKEPP oligomerization and the forma-
tion of a larger signaling complex. Furthermore, the B1 Tyr
residue of IKEPP PDZ1 is predicted to be phosphorylated (by
NetPhos analysis, available on the World Wide Web at www.
cbs.dtu.dk/services/NetPhos), which would alter the binding
specificity of the PDZ domain and may serve a regulatory
mechanism for PDZ-ligand interaction. Our laboratory is cur-
rently examining these potential regulators of IKEPP function.
Interaction of IKEPP and GCC—Although there are few
antibodies that reliably detect endogenous GCC in sections of
intestine, functional studies, in situ hybridization, and receptor
autoradiography indicate that GCC is expressed in epithelial
cells of the gastrointestinal tract (39–41). Although a more
complete analysis of IKEPP expression and distribution is
needed, our localization studies suggest that GCC and IKEPP
may be co-expressed and co-localized at the apical cell surface
FIG. 5. Targeting and activation of HA-GCC and HA-GCC4. A,
localization of HA-GCC in MDCK cells stably expressing HA-GCC (FL)
or 4 HA-GCC (4); TRITC-conjugated phalloidin was added to visu-
alize actin. xy and xz sections were analyzed by confocal microscopy
(scale bar, 10 m). B, COS7 cells were transfected with 6 g of
pCDNA.HA-GCC or pCDNA.HA-GCC4 plus 9 g of pCDNA.IKEPP or
empty vector. cGMP was assayed as described; n 	 3 with duplicate
measurements for each sample. Each bar represents total cGMP, meas-
ured from cell lysates and culture medium. Intracellular cGMP ac-
counted for at least 93% of total cGMP measured for each sample. A
corresponding Western blot indicating the relative expression of HA-
GCC and IKEPP is also shown. C, COS7 cells were transfected with
pCDNA.HA-GCC plus pCDNA.IKEPP (closed circles) or
pCDNA.HA-GCC plus empty vector (open circles). cGMP was measured
from triplicate experiments assayed in duplicate, and each data point
represents the mean 
 S.E.
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in intestinal epithelial cells (Fig. 3). Furthermore, GCC and
IKEPP directly interact in biochemical assays, and the inter-
action requires the COOH-terminal PDZ binding motif of GCC
(Fig. 4). When co-expressed in COS7 cells, HA-GCC and IKEPP
can be co-immunoprecipitated (Fig. 4E). Taken together, our
data support the hypothesis that GCC and IKEPP associate in
epithelial cells. However, consistent with previous reports (42),
we were unable to extract significant amounts of overexpressed
(MDCK cells) or endogenous GCC (T84 cells) from membranes
to directly study the GCC-IKEPP interaction in epithelial cells.
Therefore, definitive proof that IKEPP and GCC interact in
intestinal epithelial cells will require dominant-negative ap-
proaches and functional assays.
IKEPP mRNA is also abundantly expressed in the kidney
(Fig. 1, A and B). Ligand binding assays and functional studies
suggest that GCC may be expressed in the kidney in some
species (43, 44). Therefore, IKEPP and GCC may also associate
in the kidney; however, renal IKEPP complexes will probably
differ from those found in intestinal epithelial cells. Further-
more, proteins that associate with IKEPP may be differentially
expressed in distinct regions of the kidney or gastrointestinal
tract.
Functions of the GCC-IKEPP Interaction—The trafficking,
regulation, and function of GCC are poorly understood, and
there are many potential roles for the IKEPP-GCC interaction.
In well differentiated cultured epithelial cells and in intestinal
cell lysates, GCC is found in the detergent-insoluble fraction
(45). The insolubility of GCC may be due to a direct or indirect
association with cytoskeletal elements enriched at the apical
membrane. We find that 50% of the endogenous IKEPP in
cultured intestinal cells is in the cytosolic fraction (Fig. 2C),
and membrane-associated IKEPP is easily solubilized in buff-
ers containing 1% Triton X-100 (Fig. 4E). Therefore, IKEPP
does not mediate the association of GCC with the detergent-
insoluble fraction of epithelial cells. GCC exists as a functional
dimer or trimer (46–48), and it is known that interactions with
PDZ proteins can facilitate protein oligomerization (14, 36, 49).
However, the intracellular domains of GCC are not required for
oligomer formation (48), suggesting that association with
IKEPP is not likely to play an important role in this process.
Harris et al. demonstrated that deletion of the PDZ interaction
motif at the COOH terminus of the multidrug resistance-asso-
ciated protein 2 (MRP2/cMOAT) disrupted apical targeting in
transiently transfected MDCK cells (50). However, the con-
structs used in this study contained a COOH terminus green
fluorescent protein tag blocking the PDZ interaction motif and
interactions with PDZ proteins were not assessed. Moyer et al.
also reported that the efficient apical trafficking of a green
fluorescent protein-CFTR fusion protein required an intact
CFTR COOH terminus and association with PDZ proteins (51).
In contrast, Benharouga et al. find that CFTR proteins lacking
the COOH-terminal PDZ binding motif are retained at the
apical membrane in polarized MDCK II cells (52). Thus, it is
not clear whether apical membrane proteins that bind to PDZ
proteins, require the PDZ interaction for apical trafficking or
localization. We find that GCC4 was efficiently targeted to the
apical cell surface (Fig. 5A). Thus, GCC must contain apical
targeting information in other regions of the protein, and in-
teraction with PDZ proteins is not required for the efficient
surface expression or apical targeting of GCC.
Previous mutagenesis studies indicate that the COOH ter-
minus of GCC is required for catalytic function of the enzyme
(4, 53). Since association with PDZ proteins has been shown to
modulate activation and down-stream signaling of other cellu-
lar receptors (36, 54), we tested the hypothesis that association
with IKEPP regulated the catalytic activity of GCC. We found
that co-expression of IKEPP with GCC significantly decreases
STa-mediated accumulation of cGMP in transfected cells (Fig.
5B). If the GCC-IKEPP interaction occurs within an intracel-
lular compartment, co-expression of IKEPP could decrease the
number of receptors present on the cell surface. Our localiza-
tion studies suggest that IKEPP is associated with the apical
cell surface (Fig. 3), but we also observe significant amounts of
IKEPP in the subapical compartment of Caco2 cells (Fig. 3A).
However, the Vmax of the receptor was not significantly differ-
ent when IKEPP was co-expressed (Fig. 5C), indicating that
the GCC-IKEPP interaction does not dramatically change the
amount of receptor on the plasma membrane.
IKEPP-mediated inhibition of GCC is only observed in cells
expressing full-length GCC and not GCC proteins lacking the
PDZ binding motif (Fig. 5B). Thus, a physical interaction be-
tween IKEPP and GCC is required for modulation of receptor
function. Co-expression of IKEPP and GCC would decrease
STa-mediated cGMP accumulation if IKEPP decreases the af-
finity of the receptor for its ligand. Alternatively, it is possible
that intra- or intermolecular interactions between CTEP and
the GCC catalytic domain maintain the enzyme in the appro-
priate conformation for catalytic function. Binding of IKEPP to
CTEP may compete for these intra- or intermolecular interac-
tions to decrease the catalytic activity of GCC. Likewise, it is
possible that co-expression of IKEPP competes for binding of a
cytosolic factor that associates with GCC to stimulate its cat-
alytic function. It is also possible that IKEPP recruits an in-
hibitory protein to the GCC receptor complex. While the mech-
anism of the inhibition of GCC catalytic activity by IKEPP is
unclear at this time, this interaction may have important im-
plications for understanding the desensitization of GCC. Pro-
longed application of STa leads to desensitization of the endog-
enous receptor in T84 cells but not transfected receptors in
COS7 or hEK293 cells, suggesting that the desensitization may
require the presence of an accessory protein that is not ex-
pressed in these cells (29). Thus, it is intriguing to speculate
that a regulated interaction with IKEPP or the recruitment of
additional proteins to IKEPP-GCC multiprotein complexes is
required for GCC receptor desensitization. GCC null mice are
resistant to STa but have no obvious phenotype (55, 56), sug-
gesting that we have much to learn regarding the physiological
role of GCC and its endogenous ligands. We also have much to
learn about mechanisms to control GCC activation and desen-
sitization, since the acute secretory diarrhea caused by STa is
a leading cause of pediatric death worldwide. The identification
of other proteins in IKEPP-GCC complexes may help elucidate
the role of GCC in normal physiology and may provide insights
into strategies to control excessive GCC activation by STa.
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